Literature DB >> 28699928

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.

Enrico Peiretti1, Giulia Caminiti1, Rita Serra1, Lea Querques2, Riccardo Pertile3, Giuseppe Querques2.   

Abstract

PURPOSE: To evaluate the efficacy of photodynamic therapy (PDT) compared with intravitreal vascular endothelial growth factor (VEGF) inhibitors alone or combined with PDT in the treatment of choroidal neovascularization (CNV) secondary to chronic central serous chorioretinopathy (CSCR).
METHODS: Retrospective study of a consecutive series of 34 white patients (34 eyes) with angiographic evidence of choroidal neovascularization secondary to chronic central serous chorioretinopathy, divided into two groups followed for at least 12 months: 16 were treated with full fluence PDT (PDT group) and 18 with vascular endothelial growth factor inhibitors (intravitreal [IVT] group).
RESULTS: In the PDT group, mean best-corrected visual acuity (BCVA) was 20/40 (0.30 ± 0.69 logMAR) at baseline and did not change after 12 months (20/40; 0.30 ± 0.49 logMAR [P = 0.49]). In the IVT group mean, best-corrected visual acuity was 20/40 (0.30 ± 0.69 logMAR) at baseline and also did not change at the 12-month follow-up (20/32; 0.20 ± 0.49 logMAR [P = 0.20]). There was no statistically significant difference between the two groups in terms of best-corrected visual acuity. A statistical significance difference was found in central macular thickness between the two groups with a better reduction of the thickening in the PDT group (P = 0.05); moreover, indocyanine green angiography analysis revealed that 50% of the polypoidal lesions were closed after PDT and 25% of the polypoidal lesions disappeared after anti-vascular endothelial growth factor therapy at 12-month follow-up.
CONCLUSION: PDT and IVT inhibitors alone or combined show similar clinical effects in chronic central serous chorioretinopathy eyes with choroidal neovascularization.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28699928     DOI: 10.1097/IAE.0000000000001750

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  7 in total

1.  [Statement from the BVA, the DOG, and the RG on treatment of choroidal neovascularization in diseases other than neovascular age-related macular degeneration : October 2017].

Authors: 
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

2.  OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.

Authors:  Fang Zheng; Jingliang He; Zhitao Su; Ye Liu; Yufeng Xu; Lei Liu; Panpan Ye
Journal:  BMC Ophthalmol       Date:  2022-06-07       Impact factor: 2.086

Review 3.  Pathophysiology of central serous chorioretinopathy: a literature review with quality assessment.

Authors:  Pushpinder Kanda; Arnav Gupta; Chloe Gottlieb; Rustum Karanjia; Stuart G Coupland; Manpartap Singh Bal
Journal:  Eye (Lond)       Date:  2021-10-15       Impact factor: 4.456

4.  Efficacy of Navigated Laser Photocoagulation for Chronic Central Serous Chorioretinopathy: A Retrospective Observational Study.

Authors:  Fen Zhou; Jin Yao; Qin Jiang; Weihua Yang
Journal:  Dis Markers       Date:  2022-04-20       Impact factor: 3.464

5.  Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.

Authors:  Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Felix Hagenau; Christoph Kern; Tina Herold; Karsten U Kortuem; Siegfried G Priglinger; Jakob Siedlecki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-28       Impact factor: 3.117

6.  Advanced glycation end products promote VEGF expression and thus choroidal neovascularization via Cyr61-PI3K/AKT signaling pathway.

Authors:  Lijuan Sun; Tonglie Huang; Wenqin Xu; Jiaxing Sun; Yang Lv; Yusheng Wang
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379

Review 7.  The Role of Imaging in Planning Treatment for Central Serous Chorioretinopathy.

Authors:  Stefano Da Pozzo; Pierluigi Iacono; Alessandro Arrigo; Maurizio Battaglia Parodi
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.